Literature DB >> 31503108

Comparison between the Pavlik harness and the Tübingen hip flexion splint for the early treatment of developmental dysplasia of the hip.

Lin Ran1, Huimin Chen1, Yuancheng Pan1, Qingjian Lin1, Federico Canavese2, Shunyou Chen1.   

Abstract

The Pavlik harness and the Tübingen hip flexion splint (Tübingen hip flexion splint) are two effective options for the early management of patients younger than 6 months of age with developmental dysplasia of the hip (DDH). The main objective of this study was to evaluate the clinical and radiological outcomes of patients younger than 6 months of age with type IIb to IV DDH managed by Pavlik harness or Tübingen hip flexion splint. The Pavlik harness and Tübingen hip flexion splint groups were comparable regarding the affected side (P = 0.09), Graf grade (P = 0.635), and age at initial treatment (P = 0.77). Overall, failure rates were 12 and 33% in Pavlik harness (4/33 hips) and Tübingen hip flexion splint groups (14/43 hips), respectively (P = 0.038). No cases of avascular necrosis (AVN) were found in either group. In the Tübingen hip flexion splint group, the failure rate was significantly higher in bilateral cases (66.6%; P = 0.004), in severe forms (Graf grade IV hips; P ≤ 0.0001), and in patients with lower age at initial treatment (67.7 ± 39.3 days; P = 0.005). The average follow-up time was 30.35 ± 3.58 months (range: 24-36). At the last follow-up visit, no statistically significant differences were found between the Pavlik harness and Tübingen hip flexion splint groups regarding the acetabular index (t = 0.632; P = 0.53) or center-edge angle (Z = -0.303; P = 0.762). Our study showed that both the brace treatments for DDH in children younger than 6 months of age were effective and well tolerated. However, Tübingen hip flexion splint should not be used in patients with severe forms of DDH (Graf grade IV hips).

Entities:  

Mesh:

Year:  2020        PMID: 31503108     DOI: 10.1097/BPB.0000000000000667

Source DB:  PubMed          Journal:  J Pediatr Orthop B        ISSN: 1060-152X            Impact factor:   1.041


  7 in total

Review 1.  Splinting for the non-operative management of developmental dysplasia of the hip (DDH) in children under six months of age.

Authors:  Kerry Dwan; Jamie Kirkham; Robin W Paton; Emma Morley; Ashley William Newton; Daniel C Perry
Journal:  Cochrane Database Syst Rev       Date:  2022-10-10

2.  Tübingen hip flexion splint for the treatment of developmental dysplasia of the hip in children younger than six months age: a meta-analysis.

Authors:  Xinwang Zhi; Xietian Xiao; Yuwei Wan; Ping Wei; Federico Canavese; Hongwen Xu
Journal:  J Child Orthop       Date:  2021-08-20       Impact factor: 1.548

3.  Tübingen hip flexion splints for developmental dysplasia of the hip in infants aged 0-6 months.

Authors:  You Zhou; Rong Li; Chuan Li; Ping Zhou; Yan Li; You-Hao Ke; Fei Jiang; Xiao-Peng Kang
Journal:  BMC Pediatr       Date:  2020-06-05       Impact factor: 2.125

4.  Using Z-score to optimize population-specific DDH screening: a retrospective study in Hangzhou, China.

Authors:  Haomin Li; Liqi Shu; Jin Yu; Zeng Xian; Huilong Duan; Qiang Shu; Jingjing Ye
Journal:  BMC Musculoskelet Disord       Date:  2021-04-12       Impact factor: 2.362

5.  Short Term Results of Early Treatment of Developmental Dysplasia of the Hip or Luxation with Pavlik Harness in Human Position.

Authors:  Manuel Gahleitner; Rainer Hochgatterer; Gerhard Großbötzl; Lorenz Pisecky; Matthias Klotz; Tobias Gotterbarm; Günter Hipmair
Journal:  Medicina (Kaunas)       Date:  2022-01-28       Impact factor: 2.430

6.  Comparison of treatment outcomes of stable and unstable developmental dysplasia of the hip with the Tübingen splint.

Authors:  Emmelie Chaibi; Claire-Anne Saugy; Eleftheria Samara; Pierre-Yves Zambelli; Sophie Rosa Merckaert
Journal:  Front Pediatr       Date:  2022-08-25       Impact factor: 3.569

7.  The nomogram predicting the early failure rate of the Pavlik harness for developmental dysplasia of the hip in infants under 6 months of age.

Authors:  Pan Gou; Kai Gao; Xiaoting Wang; Xing Liu
Journal:  Front Pediatr       Date:  2022-10-03       Impact factor: 3.569

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.